BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA ReviewBenzinga • 05/19/21
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and IIGlobeNewsWire • 05/19/21
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/21
BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor ConferencesGlobeNewsWire • 05/04/21
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and WebcastGlobeNewsWire • 05/03/21
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual MeetingGlobeNewsWire • 04/26/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of BioXcel Therapeutics, Inc. (BTAI)Newsfile Corp • 04/16/21
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal SymptomsGlobeNewsWire • 03/31/21
FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related AgitationBenzinga • 03/15/21
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with DementiaGlobeNewsWire • 03/15/21
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/11/21
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/11/21
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and WebcastGlobeNewsWire • 03/04/21
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related AgitationGlobeNewsWire • 03/03/21
BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation StudyBenzinga • 02/25/21
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate SecretaryGlobeNewsWire • 02/23/21